# Phase II COBRE CNTN

> **NIH NIH P20** · CLEVELAND CLINIC FOUNDATION · 2021 · $819,000

## Abstract

SUMMARY/ABSTRACT
Clinical and Translational Research Core (CTRC)
The Clinical and Translational Research Core (CTRC) provides the infrastructure for neurodegenerative disease
(NDD) clinical research within the Center for Neurodegenerative and Translational Neuroscience (CNTN). In
Phase 1, the Core recruited, characterized, and retained a clinical cohort consisting of more than 190 “deeply
phenoyped” research participants across five diagnostic groups: mild cognitive impairment (MCI), mild
Alzheimer’s disease (AD), Parkinson’s disease (PD) with no cognitive impairment (PD-NC), PD with mild
cognitive impairment (PD-MCI), and cognitively normal controls (CNC). Data from this cohort directly supported
the research goals of 5 projects in Phase 1, as well several other collaborations. In Phase 2, the core will extend
the study up to ten years. As in Phase 1, the CTRC will provide each project leader with operational and
regulatory support, project management, and research instruction that will help advance them toward the goal
of independent funding. A notable enhancement of the Clinical Core in Phase 2 includes a focus on the role of
neuroinflammation in NDD. The CTRC’s multimodal approach to neuroinflammation (including neuroimaging,
blood-based biomarkers, genetics, and clinical assessments) represents one of the first comprehensive
databases in the field of NDD. In addition to sustaining the clinical core, the CTRC will focus on increasing
participation rates of traditionally underrepresented patient populations. Participation will be facilitated through
expansion of our education and outreach program. This program, which was implemented in Phase 1, is guided
by input from a Community Advisory Board (CAB) and includes an innovative education and outreach website
(Healthybrains.org). Finally, the core will also establish the first biobank in Southern Nevada at the University of
Nevada-Las Vegas (UNLV) under the direction of Dr. Jefferson Kinney. This new resource will store, analyze,
and provide expertise in the evaluation of non-clinical and clinical biospecimens. In addition to supporting the
currently proposed projects, a number of additional COBRE and non-COBRE collaborators will access this
valuable resource. The CTRC has formative and summative assessments imbedded within in that will insure
success in achieving its specific aims.

## Key facts

- **NIH application ID:** 10271794
- **Project number:** 2P20GM109025-06A1
- **Recipient organization:** CLEVELAND CLINIC FOUNDATION
- **Principal Investigator:** AARON RITTER
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $819,000
- **Award type:** 2
- **Project period:** 2015-09-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10271794

## Citation

> US National Institutes of Health, RePORTER application 10271794, Phase II COBRE CNTN (2P20GM109025-06A1). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10271794. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*